జర్నల్ ఆఫ్ క్లినికల్ & ఎక్స్‌పెరిమెంటల్ ఫార్మకాలజీ

నైరూప్య

Beneficiary Effect of Combination Therapy of Metformin and Pitavastatin Drug on Alloxan Induced Diabetic Rats Comparing to Single Drug Therapy

Tanjir Islam Md,Nasrin S,Rashid M,Sultana T,Hassan Kawsar Md,Helal Uddin Sumon Md,Didaruzzaman Sohel Md*

Background: The present study was designed to investigate the antihyperglycemic, antidyslipidemic effects and hepatoprotectivity of the fixed dose combination of metformin [850 mg/70 kg body weight (BW)] and pitavastatin [2 mg/70 kg (BW)] on alloxan induced (120 mg/kg BW) diabetic rats.
Methods: A well-established method was implemented to evaluate the effects of combination drug therapy of metformin and pitavastatin on alloxan induced diabetic rats. This study has been designed to evaluate the effects of metformin, pitavastatin and combination on blood glucose level, triglyceride (TG) level, LDL cholesterol level, total cholesterol level, liver dysfunction indices (ALT), liver dysfunction indices (AST), effect of drugs and their combination on left ventricle, survival rate of diabetic treated rats, compare weight of different groups and justify among them. The statistical method applied in each analysis was described in each figure. Results were considered to be significant when p values were less than 0.05 (p<0.05).
Results: In alloxan induced diabetic rats, combination therapy induced a significant decrease in blood glucose level from 15.5 ± 0.01 to 6 ± 0.03 mmol/L two hours after last dose administration, after daily treatment for two weeks. In case of dyslipidemic effect, combination therapy reduced total cholesterol (33%), triglyceride (36%) and LDL-cholesterol (34%) levels significantly and increased HDL-cholesterol level (67%) in comparison with their respective diabetic control groups. It was also observed that combination therapy decreased LV hypertrophy (47%) in comparison with diabetic control group effectively. It was also observed that combination therapy decreased ALT (46%) and AST (35%) in comparison with diabetic control group effectively.
Conclusion: In conclusion pitavastatin potentiates the antihyperglycemic, antidyslipidemic and hepatoprotectivity of metformin on alloxan induced diabetic rats. The results of the present study suggest that, combination of metformin and pitavastatin might be efficacious in patients with diabetic dyslipidemia and increased hepatoprotectivity.